BiotechTube

Humanized anti-CD117 Monoclonal Antibody (JSP191)

Phase 1/2Terminated
0 watching 0 views this week💤 Quiet
33
Hype Score

Development Stage

✓
Pre-clinical
2
Phase 1
3
Phase 2
4
Phase 3
5
Approved
Indication / Disease

SCID

Conditions

SCID

Trial Timeline

Mar 20, 2017 → Jul 7, 2025

NCT ID
NCT02963064

About Humanized anti-CD117 Monoclonal Antibody (JSP191)

Humanized anti-CD117 Monoclonal Antibody (JSP191) is a phase 1/2 stage product being developed by Jasper Therapeutics for SCID. The current trial status is terminated. This product is registered under clinical trial identifier NCT02963064. Target conditions include SCID.

Hype Score Breakdown

Clinical
13
Activity
8
Company
2
Novelty
4
Community
3

Clinical Trials (2)

NCT IDPhaseStatus
NCT04429191Phase 1UNKNOWN
NCT02963064Phase 1/2Terminated

Competing Products

1 competing product in SCID

See all competitors
ProductCompanyStageHype Score
busulfan + PEG-ADA ERTAllergy TherapeuticsPhase 1/2
36

Other Products from Jasper Therapeutics

BriquilimabPhase 2
44
BriquilimabPhase 1/2
33
BriquilimabPhase 1/2
33
JSP191Phase 1
25
Humanized anti-CD117 Monoclonal Antibody (JSP191)Phase 1
25